Concert Pharmaceuticals to Report First Quarter 2017 Financial Results on May 2, 2017, and Present at Upcoming Investor Conferences

LEXINGTON, Mass.–(BUSINESS WIRE)– Concert
Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will
report its first quarter 2017 financial results on Tuesday, May 2, 2017,
before the U.S. financial markets open. The Company will host a
conference call and webcast at 8:30 a.m. ET to discuss first quarter
financial results and provide a business update. Individuals interested
in participating in the call should dial (855) 354-1855 (U.S. and
Canada) or (484) 365-2865 (International).

In addition, the Company today announced that it will present a
corporate overview at the following upcoming investor conferences:

• The 42nd Annual Deutsche Bank Securities Health Care Conference on May
  3, 2017 at 2:50 p.m. ET in Boston, MA; and
• The UBS Global Healthcare Conference on May 23, 2017 at 1:30 p.m. ET
  in New York, NY.

A live webcast of these presentations, including the first quarter
financial results, may be accessed in the Investors
section of the Company’s website at www.concertpharma.com.
Please log on to the Concert website approximately 15 minutes prior to
the scheduled webcast to ensure adequate time for any software downloads
that may be required. A replay of the first quarter financial results
webcast will be available on Concert’s website for three months. A
replay of the investor conference webcasts will be available on
Concert’s website for two weeks following each presentation.

About Concert

Concert
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform® (deuterated chemical entity platform) to create novel
medicines designed to address unmet patient needs. The Company’s
approach starts with approved drugs in which deuterium substitution has
the potential to enhance clinical safety, tolerability or efficacy.
Concert has a broad
pipeline of innovative medicines targeting pulmonary diseases,
including cystic fibrosis, autoimmune and inflammatory diseases and
central nervous systems (CNS) disorders. For more information please
visit www.concertpharma.com.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170425005151/en/